PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma-Reference-Cited by-同舟云学术

PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma

Published:2018-03-14 Issue:4 Volume:11 Page:345-359
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Gaiser Maria Rita¹²,Bongiorno Michelle³,Brownell Isaac⁴

Affiliation:

1. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany

2. Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany

3. Naval Health Clinic Hawaii, Pearl Harbor, HI, USA

4. Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Funder

NCI

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2018.1445966

Reference101 articles.

1. Merkel cell carcinoma - pathogenesis, clinical aspects and treatment

2. Advances in Merkel cell carcinoma pathogenesis and management: a recently discovered virus, a new international consensus staging system and new diagnostic codes

3. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

4. Incidence and Survival for Merkel Cell Carcinoma in Queensland, Australia, 1993-2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review;Cell Death & Disease;2024-04-09

2. Immunologic tumor microenvironment modulators for turning cold tumors hot;Cancer Communications;2024-03-29

3. Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review;Dermatologic Surgery;2024-02-13

4. Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis;JEADV Clinical Practice;2023-08-07

5. Recent advancement in breast cancer treatment using CAR T cell therapy:- A review;Advances in Cancer Biology - Metastasis;2023-07